HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fluoxetine disrupts the integration of anxiety and aversive memories.

Abstract
Anxiety disorders may result from an overexpression of aversive memories. Evidence suggests that the hippocampal cholinergic system could be the point of convergence of anxiety and memory. We propose that clinically effective anxiolytics may exert their effect by interfering with this integration mechanism. To assess anxiety and aversive memory, we used the shock-probe burying test. A reduction in anxiety in this test is indicated by decreased burying, whereas impaired cognition is reflected by an increased number of probe-contacts and/or reduced retention latency. Both an aversive stimulus and the memory of that stimulus significantly increased hippocampal acetylcholine (ACh) levels (Experiment 1). In fact, the memory of the event seemed to be more important than the event itself since the aversive memory induced a greater increase in hippocampal ACh. Injections (i.p.) of fluoxetine (Prozac) reduced burying behavior, while not affecting probe contacts or retention latency (Experiment 2). Although injections of fluoxetine did not affect basal hippocampal ACh efflux (Experiment 3), fluoxetine abolished the increase in ACh induced by the aversive stimulus and the memory of that stimulus (Experiment 4), emphasizing the significance of aversive memories in anxiety disorders. These actions may be mediated by a decrease in the event-related enhancement in cholinergic neurotransmission through M1 cholinergic receptors (Experiment 5). Therefore, anxiety disorders may stem from an unopposed formation of aversive memories and clinically effective anxiolytics hinder the association between emotional and cognitive processing. This reduces the emotional impact of aversive memories, thereby opposing consequent anxiety.
AuthorsAldemar Degroot, George G Nomikos
JournalNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (Neuropsychopharmacology) Vol. 30 Issue 2 Pg. 391-400 (Feb 2005) ISSN: 0893-133X [Print] England
PMID15592351 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antidepressive Agents, Second-Generation
  • Muscarinic Antagonists
  • Fluoxetine
  • Pirenzepine
  • Acetylcholine
Topics
  • Acetylcholine (metabolism)
  • Animals
  • Antidepressive Agents, Second-Generation (therapeutic use)
  • Anxiety (drug therapy, psychology)
  • Dose-Response Relationship, Drug
  • Electroshock
  • Fluoxetine (therapeutic use)
  • Hippocampus (drug effects, metabolism)
  • Male
  • Memory
  • Memory, Short-Term (drug effects)
  • Microdialysis
  • Muscarinic Antagonists (pharmacology)
  • Parasympathetic Nervous System (drug effects, metabolism)
  • Pirenzepine (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Synaptic Transmission (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: